P 58 or 59 - Stem Cell Opportunity - Southern Cross Equities
INVESTMENT STRATEGY
We see a payoff to shareholders arising from partnering deals for individual applications as the stem cells prove themselves in clinical trials. We expect that
the first of these deals can be made in 2010. We expect a typical licensing deal will yield upfront and milestone payments as well as royalties.
Is it possible we are looking at a partnering deal as against acquisition merger? Sorry I may have missed something!
Also love your enthusiasm Pixie!
trading halt - m&a, page-22
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |